Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 6/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | F13A1 | P00488 | 3/20 | 0.43 |
| ▸ | TGM2 | P21980 | 3/20 | 0.43 |
| ▸ | TGM1 | P22735 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30466339 | 0.85 | GPR119 (0.46) | RORCEPHX2NAMPT | |
| SCHEMBL25272032 | 0.85 | GPR119 (0.46) | RORCEPHX2NAMPT | |
| SCHEMBL17394363 | 0.78 | RORC (0.52) | RORCNAMPTF13A1TGM2TGM1 | |
| SCHEMBL12627185 | 0.78 | HCRTR1 (0.50) | RORCMMP13PKM | |
| SCHEMBL1181084 | 0.78 | PKM (0.73) | PKMF13A1TGM2TGM1 | |
| SCHEMBL16434749 | 0.75 | RORC (0.48) | RORC | |
| SCHEMBL25732011 | 0.74 | GPR119 (0.41) | RORCEPHX2MMP13NAMPT | |
| SCHEMBL18418201 | 0.74 | MGLL (0.72) | RORCNAMPTPKMF13A1TGM2 | |
| SCHEMBL6273392 | 0.74 | MMP13 (0.49) | RORCMMP13PKMF13A1TGM2 | |
| SCHEMBL21911197 | 0.73 | PKM (0.52) | RORCMMP13PKMF13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773644-B1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9139593-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139593-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9139593-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFMANN-LA ROCHE AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFMANN-LA ROCHE AG (CH) | 2014-10-30 | — | — | US | disclosed |
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFMANN-LA ROCHE AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2773644-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8809552-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809552-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809552-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2013064467-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EPHX1, EPHX2, HRH2 | RORC 1620/4885EPHX2 2/4885MMP13 2621/4885 |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EPHX1, EPHX2, HRH2 | RORC 1620/4885EPHX2 2/4885MMP13 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.